Skip to NavigationSkip to content

AZ reveals compelling PhIII data for ovarian cancer treatment

Published on 26/10/16 at 05:01pm

AstraZeneca has revealed new results from a Phase III trial investigating the efficacy of its Lynparza drug as a monotherapy for the treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.

The results showed that the drug achieved a statistically significant improvement of progression-free survival (PFS) in patients compared to placebo. Median PFS also substantially exceeded what the drug recorded in its Phase II trial studying patients with platinum-sensitive relapsed ovarian cancer. Safety findings remained consistent with earlier data.

The results follow the FDA’s decision to award Lynparza Fast Track Designation earlier this year.

“We are pleased with the robust improvement in progression-free survival demonstrated by Lynparza in the SOLO-2 trial,” commented Sean Bohen, executive VP of Global Medicines Development and CMO at AstraZeneca. “We will work with regulatory authorities to make Lynparza tablets available as quickly as possible to patients with ovarian cancer. We remain committed to investigating the full potential of Lynparza, both as monotherapy and in combinations, and to identifying all patients who may benefit from this important medicine.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches